112 filings
Page 5 of 6
8-K
2wggd
8 Jan 18
Regulation FD Disclosure
12:00am
8-K
32s2k4b67 z5m8d
4 Dec 17
Departure of Directors or Certain Officers
12:00am
8-K
329zj b4p
28 Nov 17
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
12:00am
8-K
86p6do8z
7 Nov 17
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress
12:00am
8-K
vgo08 ai113tz14n5
24 Oct 17
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to
12:00am
8-K
i97bml 7o32bwc
3 Oct 17
Amgen and Cytomx Therapeutics Announce
12:00am
8-K
xaoipw z9lw02jh
7 Aug 17
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call
12:00am
8-K
usoddp8i
17 Jul 17
Changes in Registrant's Certifying Accountant
12:00am
8-K
0nd reyc1gz
29 Jun 17
CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate
12:00am
8-K
n3973x 268
28 Jun 17
CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial
12:00am
8-K
81grn8
21 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
q3p moo7h1dr96b
15 May 17
Departure of Directors or Certain Officers
12:00am
8-K
2oli821z
5 May 17
CytomX Announces First Quarter 2017 Financial Results
12:00am
8-K
f845a25bn3 r1
30 Mar 17
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
12:00am
8-K
cr6 sabjlrboe
20 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
nnohxb
2 Mar 17
CytomX Announces Full-Year 2016 Financial Results
12:00am
8-K
n2lbkdtql7luc26p8
10 Jan 17
Results of Operations and Financial Condition
12:00am
8-K
27e8j4m3sfl9w4
14 Dec 16
CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072
12:00am
8-K
ixc1 ybecc1k
13 Dec 16
CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration
12:00am
8-K
vs8p5gfp6mdhk4g erkp
5 Dec 16
CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration
12:00am